Merck & Co and Schering-Plough settle with US states on Vytorin marketing probe
This article was originally published in Scrip
Executive Summary
Merck & Co and Schering-Plough have agreed to pay the $5.4 million in legal costs incurred by 35 states and the District of Columbia regarding their probe into whether the companies violated state consumer protection laws through their use of the ENHANCE trial to market Vytorin (ezetimibe plus simvastatin) and Zetia (ezetimibe).